1. |
Huang CY, Lien R, Wang NK, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(3): 479-487. DOI: 10.1007/s00417-017-3878-4.
|
2. |
Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity[J]. Invest Ophthalmol Vis Sci, 2015, 56(2): 956-961. DOI: 10.1167/iovs.14-15842.
|
3. |
Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity[J]. Retina, 2017, 37(4): 694-701. DOI: 10.1097/IAE.0000000000001209.
|
4. |
Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity[CD]. Cochrane Database Syst Rev, 2018, 1(1): CD009734[2018-01-08]. http://europepmc.org/article/MED/29308602. DOI: 10.1002/14651858.CD009734.pub3.
|
5. |
Wu AL, Wu WC. Anti-VEGF for ROP and pediatric retinal diseases[J]. Asia Pac J Ophthalmol(Phila), 2018, 7(3): 145-151. DOI: 10.22608/APO.201837.
|
6. |
Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374.
|
7. |
Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors[J]. Ophthalmology, 2017, 124(8): 1156-1164. DOI: 10.1016/j.ophtha.2017.03.018.
|
8. |
Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial[J]. JAMA Pediatr, 2018, 172(3): 278-286. DOI: 10.1001/jamapediatrics.2017.4838.
|
9. |
Bai Y, Nie H, Wei S, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity[J]. Br J Ophthalmol, 2019, 103(4): 494-498. DOI: 10.1136/bjophthalmol-2017-311662.
|
10. |
Jin E, Yin H, Li X, et al. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity[J]. Retina, 2018, 38(8): 1595-1604. DOI: 10.1097/IAE.0000000000001763.
|
11. |
程湧, 梁建宏, 黎晓新. 康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察[J]. 中华眼底病杂志, 2017, 33(2): 144-147. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.008.Cheng Y, Liang JH, Li XX. Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2017, 33(2): 144-147. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.008.
|
12. |
张海涛, 万素华, 靳玮, 等. 康柏西普玻璃体腔注射治疗早产儿视网膜病变的疗效观察及其影响因素分析[J]. 中华眼底病杂志, 2019, 35(2): 171-175. DOI: 10.3760/cma.j.issn.1005-1015.2019.02.012.Zhang HT, Wan SH, Jin W, et al. Efficacy and related factors of intravitreal injection with conbercept for retinopathy of premature[J]. Chin J Ocul Fundus Dis, 2019, 35(2): 171-175. DOI: 10.3760/cma.j.issn.1005-1015.2019.02.012.
|
13. |
International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited[J]. Arch Ophthalmol, 2005, 123(7): 991-999. DOI: 10.1001/archopht.123.7.991.
|
14. |
Harder BC, von Baltz S, Jonas JB, et al. Intravitreal low-dosage bevacizumab for retinopathy of prematurity[J]. Acta Ophthalmol, 2014, 92(6): 577-581. DOI: 10.1111/aos.12266.
|
15. |
Hillier RJ, Connor AJ, Shafiq AE. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series[J]. Br J Ophthalmol, 2018, 102(2): 260-264. DOI: 10.1136/bjophthalmol-2017-310408.
|
16. |
Han J, Kim SE, Lee SC, et al. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison[J]. Acta Ophthalmol, 2018, 96(4): 475-478. DOI: 10.1111/aos.13004.
|
17. |
Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study[J]. JAMA Ophthalmol, 2017, 135(6): 654-656. DOI: 10.1001/jamaophthalmol.2017.1055.
|
18. |
Wallace DK, Dean TW, Hartnett ME, et al. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments[J]. Ophthalmology, 2018, 125(12): 1961-1966. DOI: 10.1016/j.ophtha.2018.05.001.
|
19. |
Cheng Y, Meng Q, Linghu D, et al. A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity[J/OL]. Sci Rep, 2018, 8(1): 10732[2018-07-16]. https://www.nature.com/articles/s41598-018-28987-6. DOI: 10.1038/s41598-018-28987-6.
|